Aspira Women's Health INC
Market Movers (8-K)
Aspira Women's Health Inc. has entered into a Subordinated Business Loan and Security Agreement for a $1.05 million term loan to refinance existing debt and fund general corporate purposes.
Capital raise
Aspira Women's Health Inc. has amended its previous filing to provide details on the separation agreement with former CEO Michael Buhle, including severance and equity vesting.
Aspira Women's Health Inc. held its 2026 annual meeting, with stockholders electing directors, approving executive compensation, amending the stock incentive plan, and ratifying the independent auditor.
Aspira Womens Health Inc. announced the closing of a private placement raising approximately $1.485 million through the sale of common stock and warrants.
Capital raise
Aspira Women's Health Inc. has entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation to advance AI-powered diagnostics in women's health.
Aspira Women's Health has appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026.
Quarterly Earnings (10-Q)
Aspira Womens Health Inc. reported continued net losses and substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and termination of a key government funding contract.
Worse than expected
Delay expected
Capital raise
Aspira Womens Health Inc. reported a reduced net loss for the second quarter of 2025, driven by significant operating expense reductions, despite a slight revenue decrease and Nasdaq delisting.
Worse than expected
Delay expected
Capital raise
Aspira Women's Health reports a slight revenue increase in Q1 2025 but faces going concern doubts amid ongoing losses and a Nasdaq delisting.
Worse than expected
Capital raise
Aspira Womens Health reported a net loss of $3.5 million for the third quarter of 2024, while navigating ongoing financial and Nasdaq listing compliance hurdles.
Worse than expected
Capital raise
Aspira Women's Health reported its second quarter 2024 results, highlighting a focus on commercial growth, product innovation, and operational efficiency.
Worse than expected
Capital raise
Aspira Women's Health reported a net loss of $4.6 million for the first quarter of 2024, while also highlighting progress in product development and commercial strategy.
Worse than expected
Capital raise
Annual Reports (10-K)
Aspira Womens Health Inc. reported a net loss of $12.78 million for 2025, with substantial doubt about its ability to continue as a going concern, despite a strategic shift aimed at profitability.
Worse than expected
Capital raise
Delay expected
10-K: Aspira Women's Health Amends Warrants, Pursues Strategic Alternatives Amidst Financial Uncertainty
Aspira Women's Health is amending warrants and seeking additional capital to address financial challenges and continue operations.
Capital raise
Worse than expected
Aspira Women's Health's 10-K filing outlines the company's share structure, voting rights, dividend policies, and compliance with regulatory requirements.
Worse than expected
Capital raise
Insider Trading (Form 4)
John Strahley, Chief Financial Officer of Aspira Women's Health Inc., received 70,000 shares of common stock on June 16, 2026.
John Strahley, Chief Financial Officer of Aspira Women's Health Inc., received 75,000 shares of common stock on June 16, 2026.
Director and 10% owner Jack W. Schuler acquired 222,222 shares and 300,000 warrants of Aspira Women's Health Inc. in a recent transaction.
Capital raise
Director Jeffrey Cohen acquired 11,112 shares of Aspira Women's Health Inc. common stock through a property settlement.
Aspira Women's Health Director Cynthia D. Hundorfean acquired 238,085 stock options with an exercise price of $0.35.
Better than expected
Aspira Women's Health Inc. Director John D. Fraser received a grant of 314,811 stock options with an exercise price of $0.35.
Proxy Statements (Def-14A)
Aspira Womens Health Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, stock incentive plan amendments, and auditor ratification.
Aspira Women's Health is seeking shareholder approval on key proposals including director elections, executive compensation, a stock incentive plan amendment, and ratification of its accounting firm at its upcoming annual meeting.
Capital raise
Aspira Women's Health is holding its annual meeting to vote on key proposals including a reverse stock split, director elections, executive compensation, and amendments to its stock incentive plan.
Worse than expected
Capital raise
DEFA14A: Aspira Womens Health Inc. Updates Stock Incentive Plan and Announces General Counsel's Resignation
Aspira Womens Health Inc. supplements its proxy statement to include the amended 2019 Stock Incentive Plan and discloses the resignation of its General Counsel, effective May 6, 2024.
Aspira Women's Health Inc. will hold its annual stockholders meeting virtually on June 22, 2021, to vote on the election of directors, executive compensation, and the ratification of the company's accounting firm.
Aspira Women's Health is holding its annual meeting on May 13, 2024, to vote on director elections, executive compensation, an amendment to the stock incentive plan, and ratification of the independent accounting firm.
New Public Companies (S-1)
Aspira Women's Health Inc. filed an S-1 registration statement for the resale of up to 16.7 million common shares by Lincoln Park Capital Fund, LLC, securing up to $10.0 million in committed equity financing.
Capital raise
Aspira Womens Health Inc. filed an S-1/A to register 29,226,527 shares of common stock for resale by existing stockholders, stemming from recent financing activities.
Delay expected
Capital raise
Aspira Women's Health Inc. filed an S-1 registration statement for the resale of 29,226,527 shares of common stock by existing selling stockholders, originating from convertible notes and warrants.
Capital raise
Aspira Women's Health is registering up to 42,683,030 shares for resale, including shares issued to Triton Funds LP, to support ongoing commercial activities and working capital.
Capital raise
S-1/A: Aspira Womens Health Files Amendment No. 1 to Form S-1 for Potential $2 Million Stock Offering
Aspira Womens Health aims to raise up to $2 million through a common stock purchase agreement, as detailed in its amended S-1 filing.
Capital raise
Aspira Women's Health aims to raise up to $2 million through the resale of common stock by Triton Funds LP, as detailed in a recent SEC filing.
Worse than expected
Capital raise
Schedule 13D - Activist Investments
Aspira Women's Health Inc. has filed an amendment to its Schedule 13D, detailing a recent purchase of common stock and warrants by Jack W. Schuler and the Jack W. Schuler Living Trust.
Capital raise
Jack W. Schuler and his Living Trust increased their beneficial ownership in Aspira Women's Health Inc. to 9.1% through a recent purchase of common stock and warrants.
Capital raise
Better than expected
Aspira Women's Health Inc. has announced that the Jack W. Schuler Living Trust, a significant beneficial owner, purchased a $200,000 senior secured convertible note, as part of a broader capital raising strategy.
Capital raise
Schedule 13G - Passive Investments
Armistice Capital, LLC and Steven Boyd have disclosed a passive beneficial ownership of 4.99% in Aspira Women's Health Inc., totaling 800,797 shares as of December 31, 2024.